MCID: HNS001
MIFTS: 36

Hansen's Disease

Categories: Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hansen's Disease

MalaCards integrated aliases for Hansen's Disease:

Name: Hansen's Disease 54 3
Leprosy 54 74

Classifications:



External Ids:

UMLS 74 C0023343

Summaries for Hansen's Disease

NIH Rare Diseases : 54 Hansen's disease (also known as leprosy) is a rare bacterial infection that affects the skin, nerves and mucous membranes. After exposure, it may take anywhere from 2 to 10 years to develop features of the condition. Once present, common signs and symptoms include skin lesions; muscle weakness or paralysis; eye problems that may lead to blindness; nosebleeds; severe pain; and/or numbness in the hands, feet, arms and legs. Hansen's disease is caused by the bacterium Mycobacterium leprae; however, the way in which the bacterium is transmitted (spread) is poorly understood. It appears that only about 5% of people are susceptible to the condition. Hansen's disease is easily treated with combination antibiotics for 6 months to 2 years.

MalaCards based summary : Hansen's Disease, also known as leprosy, is related to leprosy 1 and indeterminate leprosy. An important gene associated with Hansen's Disease is ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2). The drugs Dapsone and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and eye.

Wikipedia : 77 Leprosy, also known as Hansen''s disease (HD), is a long-term infection by the bacteria Mycobacterium... more...

Related Diseases for Hansen's Disease

Diseases related to Hansen's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 411)
# Related Disease Score Top Affiliating Genes
1 leprosy 1 12.6
2 indeterminate leprosy 12.6
3 leprosy 5 12.4
4 leprosy 2 12.3
5 leprosy 4 12.3
6 leprosy 6 12.3
7 leprosy 3 11.6
8 trigeminal trophic syndrome 11.5
9 buruli ulcer 11.4
10 chronic rhinitis 11.4
11 fetal thalidomide syndrome 11.4
12 macs syndrome 11.0
13 mycobacterium kansasii 11.0
14 neuropathy 10.3
15 lagophthalmos 10.3
16 hepatitis 10.3
17 australia antigen 10.2
18 pelger-huet anomaly 10.1
19 hepatitis b 10.1
20 malaria 10.1
21 psoriasis 10.1
22 systemic lupus erythematosus 10.1
23 sarcoidosis 1 10.1
24 tetanus 10.1
25 hepatitis c 10.1
26 pulmonary tuberculosis 10.1
27 molluscum contagiosum 10.1
28 onchocerciasis 10.0
29 human immunodeficiency virus infectious disease 10.0
30 carpal tunnel syndrome 10.0
31 mononeuropathy of the median nerve, mild 10.0
32 lymphoma 10.0
33 tuberculoid leprosy 10.0
34 filariasis 10.0
35 yemenite deaf-blind hypopigmentation syndrome 10.0
36 elephantiasis 10.0
37 mucocutaneous leishmaniasis 10.0
38 anterior uveitis 10.0
39 dysautonomia 10.0
40 mycosis fungoides 9.9
41 mycobacterium tuberculosis 1 9.9
42 yaws 9.9
43 allergic hypersensitivity disease 9.9
44 antiphospholipid syndrome 9.9
45 scabies 9.9
46 iridocyclitis 9.9
47 hepatitis c virus 9.9
48 cataract 9.9
49 crohn's disease 9.9
50 granuloma annulare 9.9

Graphical network of the top 20 diseases related to Hansen's Disease:



Diseases related to Hansen's Disease

Symptoms & Phenotypes for Hansen's Disease

Drugs & Therapeutics for Hansen's Disease

Drugs for Hansen's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dapsone Approved, Investigational Phase 4,Phase 1,Phase 2 80-08-0 2955
2
leucovorin Approved Phase 4,Phase 1,Phase 2,Not Applicable 58-05-9 143 6006
3
Clofazimine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 2030-63-9 2794
4
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1 13292-46-1 5381226 5458213
5
Isoniazid Approved, Investigational Phase 4,Phase 1 54-85-3 3767
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 59-30-3 6037
7 Antimalarials Phase 4,Phase 1,Phase 2
8 Folic Acid Antagonists Phase 4,Phase 1,Phase 2,Not Applicable
9 Vitamin B9 Phase 4,Phase 1,Phase 2,Not Applicable
10 Antiparasitic Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
11 Antiprotozoal Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
12 Vitamin B Complex Phase 4,Phase 1,Phase 2,Not Applicable
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Folate Phase 4,Phase 1,Phase 2,Not Applicable
15 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Vitamins Phase 4
17 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
19 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
21 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Hypolipidemic Agents Phase 4,Phase 1
23 Antimetabolites Phase 4,Phase 1,Not Applicable
24 Lipid Regulating Agents Phase 4,Phase 1
25 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
28
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Not Applicable 50-24-8 5755
29
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Not Applicable 302-25-0
30
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 3 22916-47-8 4189
31
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3,Not Applicable 2921-57-5
32
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Not Applicable 83-43-2 6741
33
Aluminum sulfate Approved Phase 2, Phase 3,Phase 3 10043-01-3
34
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
35
Goserelin Approved Phase 3 65807-02-5 5311128 47725
36
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
37
Clindamycin Approved, Vet_approved Phase 3 18323-44-9 29029
38
Benzoyl peroxide Approved Phase 3 94-36-0 7187
39
Streptomycin Approved, Vet_approved Phase 2, Phase 3,Phase 1 57-92-1 19649
40
Moxifloxacin Approved, Investigational Phase 2, Phase 3,Phase 1 354812-41-2, 151096-09-2 152946
41
Ethinyl Estradiol Approved Phase 2, Phase 3,Phase 1 57-63-6 5991
42
Polyestradiol phosphate Approved Phase 2, Phase 3,Phase 1 28014-46-2
43
Estradiol Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 50-28-2 5757
44
Norgestimate Approved, Investigational Phase 2, Phase 3,Phase 1 35189-28-7 6540478
45
Amitriptyline Approved Phase 3 50-48-6 2160
46
Perphenazine Approved Phase 3 58-39-9 4748
47
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
48
Infliximab Approved Phase 3 170277-31-3
49
Bedaquiline Approved Phase 2, Phase 3 843663-66-1
50
Clarithromycin Approved Phase 2, Phase 3 81103-11-9 84029

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy Completed NCT01290744 Phase 4 Clofazimine;Placebo
3 Uniform Multidrug Therapy Regimen for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
4 Effect of Weight and/or Obesity on Dapsone Drug Concentrations Completed NCT01165840 Phase 4 Dapsone
5 Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya Completed NCT00850915 Phase 4
6 Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine Recruiting NCT03519568 Phase 4
7 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
8 Ciclosporin in the Management of New Type 1 Reactions in Leprosy Completed NCT00919815 Phase 2, Phase 3 Ciclosporin;Prednisolone
9 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
10 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
11 Efficacy and Safety of Immunomodulator as an Adjunct Therapy in New Pulmonary Tuberculosis(Category I) Patients. Completed NCT00341328 Phase 3
12 Efficacy and Safety Study of Immunomodulator as an Adjunct Therapy in Pulmonary Tuberculosis (TB) Retreatment Patients Completed NCT00265226 Phase 3
13 Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer Completed NCT00004635 Phase 3 Thalidomide;leuprolide acetate;goserelin
14 Efficacy Trial on Oral Miltefosine in Comparison With Glucantime in the Treatment of ACL Caused by L. Tropica Completed NCT00351520 Phase 3 Miltefose
15 To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel Completed NCT02005666 Phase 3 Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel;DUAC® Gel;Placebo
16 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Recruiting NCT03662022 Phase 3 Rifampicin
17 Treatment of Neuropathic Pain in Leprosy Recruiting NCT03324035 Phase 3 Amitriptyline;Placebo oral capsule;Tramadol
18 Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors Recruiting NCT03221166 Phase 3 Thalidomide;Infliximab
19 WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8 Active, not recruiting NCT01659437 Phase 2, Phase 3 Clarithromycin Extended Release;Streptomycin intramuscular injection
20 Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial Not yet recruiting NCT03942354 Phase 2, Phase 3 Bedaquiline;Pretomanid;Moxifloxacin;Linezolid;Clofazimine;Directly observed therapy (DOT)
21 Leprosy Skin Test Antigens Trial Completed NCT00128193 Phase 2
22 Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy Completed NCT00919451 Phase 2 ciclosporin
23 Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum Completed NCT00919776 Phase 2 prednisolone;ciclosporin
24 Ciclosporin in the Management of New Erythema Nodosum Leprosum Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
25 Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas Completed NCT00047879 Phase 2 Thalidomide
26 Progression of HIV-Disease Under Low Dose Corticosteroids Completed NCT01299948 Phase 2 Prednisolone
27 A Study to Evaluate the Efficacy and Safety of Bedaquiline (TMC207) in Participants With Multibacillary Leprosy Recruiting NCT03384641 Phase 2 Bedaquiline 200 mg
28 CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
29 Efficacy and Safety of Low Dose Thalidomide in Thalassemia Intermedia Recruiting NCT03651102 Phase 2 Thalidomide Oral Product
30 Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients Not yet recruiting NCT03947437 Phase 1, Phase 2
31 Virgin Coconut Oil Oral Supplementation for Leprosy Patients Withdrawn NCT01885611 Phase 1, Phase 2
32 Prevention of Disability: Proposal for a Guidance Manual for Leprosy Patients Completed NCT01006759 Phase 1
33 Leprosy Skin Test Antigens Phase 1 Completed NCT01920750 Phase 1
34 Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers Completed NCT03302897 Phase 1
35 Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine Completed NCT00654316 Phase 1
36 Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
37 Low Level Laser Therapy Effects in Peripheral Nerves Patient With Leprosy. Unknown status NCT03072004 Not Applicable
38 Montelukast in ENL Reaction Unknown status NCT00406861 Not Applicable montelukast in treatment of ENL reaction
39 Microcirculatory Impairment in Patients With Leprosy Completed NCT02085317 Not Applicable acetylcholine Iontophoresis;sodium nitroprusside Iontophoresis
40 Molecular Epidemiology of Leprosy - Philippines Completed NCT00315809
41 The Use of Low Level Laser Therapy for Wound Healing in Leprosy Patients Completed NCT00860717 Not Applicable
42 Molecular and Immunological Tools for Detection of Strain Diversity, Drug Resistance and Immunological Responses Completed NCT00138437
43 Impact of the Virtual Human Project on Team-based Learning: A Randomized-controlled Trial Completed NCT02484469 Not Applicable
44 SMF to Improve Performance of Microscopy for the Diagnosis of PTB in a High HIV Prevalence Setting Completed NCT02701439
45 CD8 Reactivity to Microorganisms in Blood and Breast Milk Completed NCT03084614
46 γ-irradiated BCG to Train Innate Immunity Completed NCT02259608 Not Applicable
47 Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy Completed NCT00720980
48 Platelet Rich Plasma and Perineural Injection Therapy for Carpal Tunnel Syndrome Completed NCT02696161 Not Applicable
49 Genetics of Hepatitis C Virus Infection Completed NCT00005657
50 Toll-like Receptor 2 Gene Polymorphism, Serum Cytokines and Susceptibility to Disease Severity or Treatment Response of Pulmonary Tuberculosis Completed NCT00772408

Search NIH Clinical Center for Hansen's Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Hansen's Disease

Anatomical Context for Hansen's Disease

MalaCards organs/tissues related to Hansen's Disease:

42
Skin, Testes, Eye, T Cells, Bone, Prostate, Heart

Publications for Hansen's Disease

Articles related to Hansen's Disease:

(show top 50) (show all 3335)
# Title Authors Year
1
Trichoscopic findings of eyebrow alopecia in patients with multibacillary leprosy. ( 30613952 )
2019
2
Lucio phenomenon mimicking antiphospholipid syndrome: The occurrence of antiphospholipid antibodies in a leprosy patient. ( 30666664 )
2019
3
Mid borderline leprosy in type Bα Blaschko linear pattern: a rare phenomenon. ( 30345504 )
2019
4
Leprosy neuropathy masquerading as cellulitis. ( 30918118 )
2019
5
Acute renal failure by rapidly progressive glomerulonephritis with IgA deposition in a patient concomitantly diagnosed with multibacillary Hansen's disease: a case report. ( 30160772 )
2019
6
Hansen's disease. ( 31036705 )
2019
7
Molecular epidemiology of locally acquired Hansen's disease in Central Florida. ( 30654071 )
2019
8
Orthotic treatment for refractory plantar ulcers using distribution assessments of sensory disturbance and dynamic plantar pressure in patients with Hansen's disease: A case series. ( 30714641 )
2019
9
Hansen's disease deformities in a high risk area in Mozambique: A case study. ( 30726314 )
2019
10
Physical disability and Hansen's disease in Brazil in the 21st century: Brief analysis. ( 30726477 )
2019
11
Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea. ( 30970433 )
2019
12
Clinico-immunological spectrum of American tegumentary leishmaniasis and leprosy coinfection: A case series in Southeastern Brazil. ( 30994795 )
2019
13
Borderline Lepromatous Leprosy: Uncommon Clinical Presentation. ( 30211733 )
2019
14
Mycobacterium lepromatosis Lepromatous Leprosy in US Citizen Who Traveled to Disease-Endemic Areas. ( 30666944 )
2019
15
Does histoid leprosy represent a locally hyperimmune variant of lepromatous leprosy? ( 30778548 )
2019
16
Lepromatous leprosy masquerading as anetoderma in a boy. ( 30829294 )
2019
17
Borderline lepromatous leprosy masking as tinea versicolor. ( 30891732 )
2019
18
Increased CD5+ B-cells are associated with autoimmune phenomena in lepromatous leprosy patients. ( 30904499 )
2019
19
Visibly enlarged peripheral nerves in lepromatous leprosy. ( 30910939 )
2019
20
Diagnostic delay in a patient with reactional lepromatous leprosy treated as testicular tuberculosis. ( 31090835 )
2019
21
Neurosurgical treatment of leprosy neuropathy in a low-incidence, European country. ( 30903414 )
2019
22
Verrucous carcinoma on the foot arising in a chronic neuropathic ulcer of leprosy. ( 30841011 )
2019
23
Unusual association of leprosy with Lucio phenomenon with secondary antiphospholipid antibody syndrome and ischemic stroke. ( 30688250 )
2019
24
Comment on "Ichthyosiform sarcoidosis: a mimic of leprosy?" ( 30822369 )
2019
25
Ichthyosiform sarcoidosis: a mimic of leprosy? Reply from authors. ( 30903704 )
2019
26
Brain and Spinal Cord Lesions in Leprosy: A Magnetic Resonance Imaging-Based Study. ( 30761984 )
2019
27
Correspondence to histoid leprosy: a retrospective clinicopathological study from central Nepal. ( 30773622 )
2019
28
British Red Squirrels Remain the Only Known Wild Rodent Host for Leprosy Bacilli. ( 30775369 )
2019
29
De novo histoid leprosy in a Colombian patient with multiple skin nodules on the ears and extremities. ( 30785530 )
2019
30
Risk factors for physical disability upon release from multidrug therapy in new cases of leprosy at a referral center in Brazil. ( 30785567 )
2019
31
A 10-year Retrospective Descriptive Study on Pure Neuritic Leprosy from a Tertiary Referral Centre. ( 30788282 )
2019
32
Leprosy in a Midwestern Dermatology Clinic: Report of 9 Patients. ( 30799052 )
2019
33
Comment on "Bullous Erythema Nodosum Leprosum as the First Manifestation of Multibacillary Leprosy: A Rare Phenomenon". ( 30801346 )
2019
34
Umbilicated Lesions in a de novo case of histoid leprosy. ( 30821419 )
2019
35
Transepidermal elimination: Role in leprosy transmission. ( 30829298 )
2019
36
Quantitative polymerase chain reaction in paucibacillary leprosy diagnosis: A follow-up study. ( 30835722 )
2019
37
Evaluation of the cutaneous sensation of the face in patients with different clinical forms of leprosy. ( 30870498 )
2019
38
Development and evaluation of a droplet digital PCR assay for the diagnosis of paucibacillary leprosy in skin biopsy specimens. ( 30883558 )
2019
39
Leprosy in the post-elimination era: a clinico-epidemiological study from a northern Indian tertiary care hospital. ( 30901062 )
2019
40
Spatial clustering, social vulnerability and risk of leprosy in an endemic area in Northeast Brazil: an ecological study. ( 30903718 )
2019
41
Dirt, Saliva and Leprosy: Anti-Inflammatory and Anti-Infectious Effects. ( 30909425 )
2019
42
Factors Associated with Multibacillary Leprosy in a Priority Region for Disease Control in Northeastern Brazil: A Retrospective Observational Study. ( 30911302 )
2019
43
Leprosy in French Polynesia. ( 30911399 )
2019
44
Case Report: A Case of Type 1 Leprosy Reaction and Dapsone Hypersensitivity Syndrome Complicating the Clinical Course of Multibacillary Leprosy. ( 30915953 )
2019
45
Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy. ( 30916737 )
2019
46
Dual RNA-Seq of Human Leprosy Lesions Identifies Bacterial Determinants Linked to Host Immune Response. ( 30917313 )
2019
47
An innovative approach to screening and chemoprophylaxis among contacts of leprosy patients in low endemic settings: experiences from Cambodia. ( 30921325 )
2019
48
Leprosy in red squirrels in the UK. ( 30926706 )
2019
49
Impact of urbanization on tuberculosis and leprosy prevalence in medieval Denmark. ( 30942817 )
2019
50
Investigating dietary patterns and organisational structure by using stable isotope analysis: a pilot study of the Danish medieval leprosy hospital at Næstved. ( 30942818 )
2019

Variations for Hansen's Disease

Expression for Hansen's Disease

Search GEO for disease gene expression data for Hansen's Disease.

Pathways for Hansen's Disease

GO Terms for Hansen's Disease

Sources for Hansen's Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....